

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinopharm Tech Holdings Limited

國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8156)

VOLUNTARY ANNOUNCEMENT IN RELATION TO COOPERATION AGREEMENT WITH TENCENT CLOUD

This announcement is made by Sinopharm Tech Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep the shareholders and potential investors of the Company informed of the latest business development of the Group.

As at the date of this announcement, the Group is pleased to announce that a wholly-owned subsidiary of the Company, Shenzhen Guoke Anti-counterfeiting Technology Co., Ltd. (“**Guoke Anti-counterfeiting**”) and Tencent Cloud Computing (Beijing) Co., Ltd. (“**Tencent Cloud**”), have entered into a cooperation agreement, pursuant to which the parties intend to jointly explore potential cooperation opportunities. The agreed content of cooperation of the cooperation agreement is as follows:

1. Based on Tencent Reassurance Platform of Tencent Cloud and Anti-counterfeiting device with lottery (“**ACL**”) of Guoke Anti-counterfeiting, both parties jointly explore to create joint product, build a system of traceability, anti-counterfeit and marketing, which will be applied in agricultural and sideline products industry;
2. Based on the joint product of “Tencent Reassurance Platform + ACL”, both parties explore the cooperation in traceability and anti-counterfeit in the traditional Chinese medicine industry;
3. Based on blockchain technology of Tencent, both parties jointly explore cooperation in NFT (non-fungible token) digital collectables, helping in the promotion of intangible cultural heritage;
4. The specific promotion and operation arrangement of the joint products shall be separately agreed and confirmed by both parties in writing.

The above content of cooperation listed in the cooperation agreement is the intention of both parties only, and the intention of cooperation is non-exclusive. Both parties will make reasonable commercial efforts in the realization of such intention, and will sign a specific cooperation agreement after reaching a consensus. The cooperation agreement is effective for two years.

ACL is patent-protected and has four main features, namely, “anti-counterfeit”, “credibility”, “marketability” and “social responsibility”, and has a comprehensive chain of anti-counterfeit system together with anti-counterfeit packaging and online anti-counterfeit verification platform. ACL can also has various functions and properties depending on different application scenarios, redefining the traditional anti-counterfeit technology and attracting consumers to actively participate in the authentication of products. Through the “Trio Code in One” (三碼合一) entrance, consumers could easily enter the online anti-counterfeit verification platform, forming a closed loop of functions such as authentication of products and interactive marketing, thus creating a unique marketing angle.

ACL enables Corporate Social Responsibility (“CSR”). The Group, through ACL, is providing its customers with the tools to achieve a greater level of CSR. The very nature of ACL embeds the elements of consumer protection as well as contributing to the social welfare and sports development funds, two of the most important elements in CSR. By leveraging the capabilities of the ACL regarding brand protection and brand endorsement, it is expected to support the sustainable development of the brand, achieve prosperity of the industries and its high-quality development and promote rural vitalization. By using ACL, the corporate users will be able to achieve CSR in an effective way. The wide and extensive reach of ACL in consumer products will take CSR to a new level of achievement. The Group will also be able to achieve and enhance the Group’s participation in CSR through supplying ACL.

By order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
CHAN Ting
Chairperson

Hong Kong, 24 May 2022

As at the date of this announcement, the Board comprises Mr. CHAN Ting, Mr. LIAO Zhe and Mr. CHEUK Ka Chun Kevin as executive Directors, Madam CHEUNG Kwai Lan and Dr. CHENG Yanjie as non-executive Directors and Mr. LAU Fai Lawrence, Dr. LIU Ta-pei and Mr. CHAU Wai Wah Fred as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the GEM website at www.hkgem.com for a minimum period of 7 days from the date of its publication and on the website of the Company at www.sinopharmtech.com.hk.